MicroRNAs (miRNAs) are small non-coding RNA molecules that regulate gene expression by binding to target messenger RNA (mRNA) molecules and promoting their degradation or blocking their translation. Parkinson’s disease (PD) is a neurodegenerative disorder caused by the loss of dopaminergic neurons in the substantia nigra. There is increasing evidence to suggest that miRNAs play a role in the pathogenesis of PD. Studies have identified several miRNAs that are dysregulated in the brains of PD patients, and animal models of the disease. MiRNA expression dysregulation contributes to the onset and progression of PD by modulating neuroinflammation, oxidative stress, and protein aggregation genes. Moreover, miRNAs have emerged as potential therapeutic targets for PD. This review elucidates the changes in miRNA expression profiles associated with PD, emphasising their potential as diagnostic biomarkers and therapeutic targets, and detailing specific miRNAs implicated in PD and their downstream targets. Integrated Insights into miRNA Function, Microglial Activation, Diagnostic, and Treatment Prospects in PD Note: This figure is an original figure created by the authors.
Cardiovascular disease is the leading cause of mortality worldwide. Atherosclerosis constitutes most cardiovascular disease etiologies. Atherosclerosis is a chronic inflammatory and lipid-driven disease affecting the intima of blood vessels, resulting in an increase in its thickness and, therefore, narrowing of the arterial lumen. Many blood and immune cells have been shown to be implicated in atherosclerosis pathophysiology. Neutrophils are among those cells with their novel function of forming neutrophil extracellular traps. Neutrophil extracellular traps are mesh-like structures formed and released on activation of neutrophils. These structures consist of decondensed chromatin, histones, and other components, including nuclear and cellular proteins, cytoskeleton, proteases, and azurophilic granules. Neutrophil extracellular traps contain these elements and hold other circulating elements in the blood, such as tissue factor, fibrin, and other coagulation factors. Neutrophil extracellular traps are also implicated in the pathogenesis of atherothrombosis, which evolves as a consequence of atherosclerosis. In this review, we aim to demonstrate the process of neutrophil extracellular traps formation, release, and interaction with other blood cells, meaning it could be possible to use neutrophil extracellular traps as a therapeutic target in deceleration of atherosclerosis progression. Impact statement: Fatal consequences of atherosclerosis and atherothrombosis give research in this field great importance. This review provides recent information about the implications of neutrophils in the pathophysiology of atherosclerosis and atherothrombosis via formation and release of neutrophil extracellular traps (NETs), thereby enhancing our understanding on how the process of atherosclerosis develops and how its consequences occur. Information provided in this review suggests NETs as a new therapeutic target and a rich point for research. This review gives answers to questions about the mechanisms of atherosclerosis and atherothrombosis progression through studying the implications of NETs in these processes.
Purpose: Osteoporosis is a chronic metabolic bone disease characterized by reduced bone mass, microarchitectural deterioration, and an increased risk of fractures. Alongside osteoporosis, sarcopenia—the age-related decline in skeletal muscle mass and strength—is commonly observed in the elderly, especially among women. Prior studies have linked vertebral compression fractures with impaired spinal mobility, muscle atrophy, fatty degeneration of paraspinal muscles, and balance deficits. However, the relationship between osteoporosis in the absence of vertebral fractures and the condition of paraspinal muscles remains unclear. This study aimed to investigate whether osteoporosis is associated with fatty infiltration of the paraspinal muscles in patients experiencing chronic low back pain. Methods: Age- and sex-matched patients with and without osteoporosis, all presenting with chronic low back pain, were retrospectively assessed using lumbar magnetic resonance imaging. Evaluations included the degree of intervertebral disc degeneration (IVDD), Modic changes, and fat infiltration in the multifidus, erector spinae, and psoas muscles at all lumbar levels. Results: No significant differences were found between osteoporotic and non-osteoporotic groups regarding the severity of IVDD or the presence of Modic changes. However, patients with lumbar spine osteoporosis exhibited significantly greater fatty infiltration in the psoas muscle at the L1–L2 (odds ratio [OR] = 6.191; p = 0.015), L2–L3 (OR = 3.205; p = 0.028), and L5–S1 (OR = 1.564; p = 0.040) levels. Additionally, those with femoral neck osteoporosis demonstrated greater fat infiltration in the psoas muscle specifically at L1–L2 (OR = 4.487; p = 0.043). Conclusion: Osteoporosis appears to be associated with increased fatty infiltration of the psoas muscle, particularly at the upper lumbar levels. Therefore, detailed evaluation of the psoas muscle should be considered in osteoporotic patients. Conversely, the presence of fat-infiltrated psoas muscles at upper lumbar levels may warrant clinical suspicion for underlying osteoporosis. Management strategies for osteoporosis should incorporate interventions aimed at enhancing the quality and strength of the psoas muscle to help prevent vertebral compression fractures.
3 December 2024 in Clinical Neurology and Neurosurgery
Verteporfin and 5-ALA are used for visualizing malignant tissue components in different body tumors and as photodynamic therapy in treating isocitrate dehydrogenase (IDH) wild-type glioblastoma (GBM). Additionally, verteporfin interferes with Yes-associated protein 1 (YAP)/Transcriptional coactivator with PDZ-binding motif - TEA domain (TAZ-TEAD) pathway, thus inhibiting the downstream effect of these oncogenes and reducing the malignant properties of GBM. Animal studies have shown verteporfin to be successful in increasing survival rates, which have led to the conduction of phase 1 and 2 clinical trials to further investigate its efficacy in treating GBM. In this article, we aimed to review the novel mechanism of verteporfin’s action, the impact of its interaction with YAP/TAZ-TEAD, its effect on glioblastoma stem cells, and its role in inducing ferroptosis.